Evidence map›Paper›PMID 37790572›Full record

ArticlemedRxiv : the preprint server for health sciences2023

Dopamine pathway and Parkinson's risk variants are associated with levodopa-induced dyskinesia.

Yuri L Sosero, Sara Bandres-Ciga, Bart Ferwerda, Maria T P Tocino, Dìaz R Belloso, Pilar Gómez-Garre, Johann Faouzi, Pille Taba, Lukas Pavelka, Tainà M Marques and 27 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

37 authors at 19 institutions in 10 countries.

Yuri L SoseroDepartment of Human Genetics, McGill University, Montréal, QC, Canada.
Sara Bandres-CigaCenter for Alzheimer's and Related Dementias (CARD), National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes on Health, Bethesda, MD, USA.
Bart FerwerdaDepartment of Clinical Epidemiology and Biostatistics, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.
Maria T P TocinoUnidad de Trastornos del Movimiento, Servicio de Neurología y Neurofisiología Clínica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla, Spain.
Dìaz R BellosoUnidad de Trastornos del Movimiento, Servicio de Neurología y Neurofisiología Clínica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla, Spain.
Pilar Gómez-GarreUnidad de Trastornos del Movimiento, Servicio de Neurología y Neurofisiología Clínica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla, Spain.
Johann FaouziSorbonne Université, Paris Brain Institute - ICM, Inserm, CNRS, Assistance Publique Hôpitaux de Paris, Department of Neurology, Pitié-Salpêtrière Hospital, Paris, France.
Pille TabaDepartment of Neurology and Neurosurgery, Institute of Clinical Medicine, University of Tartu, Tartu 50406, Estonia.
Lukas PavelkaTransversal Translational Medicine, Luxembourg Institute of Health (LIH), Strassen, Luxembourg.
Tainà M MarquesTransversal Translational Medicine, Luxembourg Institute of Health (LIH), Strassen, Luxembourg.
Clarissa P C GomesTranslational Neuroscience, Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Esch-sur-Alzette, Luxembourg.
Alexey KolodkinTransversal Translational Medicine, Luxembourg Institute of Health (LIH), Strassen, Luxembourg.
Patrick MayTransversal Translational Medicine, Luxembourg Institute of Health (LIH), Strassen, Luxembourg.
Lukasz M MilanowskiDepartment of Neurology Faculty of Health Science, Medical University of Warsaw, Warsaw, Poland.
Zbigniew K WszolekDepartment of Neurology, Mayo Clinic Florida, Jacksonville, Florida, USA.
Ryan J UittiDepartment of Neurology, Mayo Clinic Florida, Jacksonville, Florida, USA.
Peter HeutinkGerman Center for Neurodegenerative Diseases (DZNE).
Jacobus J van HiltenDepartment of Neurology, Leiden University Medical Center, Leiden.
David K SimonDepartment of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School.
Shirley EberlyDepartment of Biostatistics and Computational Biology at the University of Rochester School of Medicine and Dentistry.
Ignacio AlvarezDepartment of Neurology, Hospital Universitari Mutua de Terrassa, Barcelona, Spain.
Lynne KrohnDepartment of Human Genetics, McGill University, Montréal, QC, Canada.
Eric YuDepartment of Human Genetics, McGill University, Montréal, QC, Canada.
Kathryn FreemanDepartment of Human Genetics, McGill University, Montréal, QC, Canada.
Uladzislau RudakouDepartment of Human Genetics, McGill University, Montréal, QC, Canada.
Jennifer A RuskeyThe Neuro (Montreal Neurological Institute-Hospital), McGill University, Montréal, QC, Canada.
Farnaz AsayeshThe Neuro (Montreal Neurological Institute-Hospital), McGill University, Montréal, QC, Canada.
Manuel Menéndez-GonzàlezFacultad de Medicina y Ciencias de la Salud, Universidad de Oviedo, Calle Julián Clavería s/n, 33006 Oviedo, Spain.
Pau PastorDepartment of Neurology, Hospital Universitari Mutua de Terrassa, Barcelona, Spain.
Owen A RossDepartment of Neurology, Mayo Clinic Florida, Jacksonville, Florida, USA.
Rejko KrügerTransversal Translational Medicine, Luxembourg Institute of Health (LIH), Strassen, Luxembourg.
Jean-Christophe CorvolCREST, ENSAI, Campus de Ker-Lann, 51 Rue Blaise Pascal - BP 37203 35172 Bruz Cedex, France.
Sulev KoksCentre for Molecular Medicine and Innovative Therapeutics, Murdoch University, Murdoch, Australia.
Pablo MirUnidad de Trastornos del Movimiento, Servicio de Neurología y Neurofisiología Clínica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla, Spain.
Rob M A De BieDepartment of Neurology and Clinical Neurophysiology, Amsterdam University Medical Centers, Amsterdam Neuroscience, University of Amsterdam, Amsterdam, The Netherlands.
Hirotaka IwakiCenter for Alzheimer's and Related Dementias (CARD), National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes on Health, Bethesda, MD, USA.
Ziv Gan-OrDepartment of Human Genetics, McGill University, Montréal, QC, Canada.
Montreal Neurological Institute and Hospital · CABiomedical Research Networking Center on Neurodegenerative Diseases · ESCentre Hospitalier de Luxembourg · LUJacksonville College · USLuxembourg Institute of Health · LUMútua Terrassa · ESAmsterdam Neuroscience · NLAmsterdam University Medical Centers · NLCentre National de la Recherche Scientifique · FRGerman Center for Neurodegenerative Diseases · DELeiden University Medical Center · NLMedical University of Warsaw · PLMurdoch University · AUNational Institute of Neurological Disorders and Stroke · USNational Institutes of Health · USUniversidad de Oviedo · ESUniversité Clermont Auvergne · FRUniversity of Luxembourg · LUUniversity of Tartu · EE

Funding

Technology and Remote Assessment CoreU19AG063911 · NIA · MAYO CLINIC ROCHESTER · PI ADAM L. BOXER · 2019 to 2026
$120.9M
Genetic characterization of atypical parkinsonismZIANS003154 · NINDS · NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE · PI SCHOLZ, SONJA · 2016 to 2025
$15.4M
Genome wide SNP analysis in Parkinson's diseaseZIAAG000949 · NIA · NATIONAL INSTITUTE ON AGING · PI SINGLETON, ANDREW · 2009 to 2024
$12.6M
Parkinson's Disease Data Organizing CenterU01NS050095 · NINDS · UNIVERSITY OF ROCHESTER · PI KURLAN, ROGER M · 2004 to 2010
$7.3M
Intramural NIH HHS ZIA AG000949Intramural NIH HHS ZIA NS003154NIA NIH HHS U19 AG063911NINDS NIH HHS U01 NS050095Wellcome Trust
6 · The paper itself

Abstract

Background: Levodopa-induced dyskinesia (LID) is a common adverse effect of levodopa, one of the main therapeutics used to treat the motor symptoms of Parkinson's disease (PD). Previous evidence suggests a connection between LID and a disruption of the dopaminergic system as well as genes implicated in PD, including Objectives: To investigate the effects of genetic variants on risk and time to LID. Methods: We performed a genome-wide association study (GWAS) and analyses focused on Results: We found that Conclusions: This study suggests that variants implicated in PD and in the dopaminergic transmission pathway play a role in the risk/time to develop LID. Further studies will be necessary to examine how these findings can inform clinical care.

Indexed as

dopamineGBA1levodopa-induced dyskinesiaLRRK2Parkinson’s disease

Identifiers

PMID37790572
PMCPMC10543218
OpenAlexW4386274661

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.